Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course. However, the investigators expect survivors from severe COVID-19 to experience persistent functional impairments, as demonstrated in prior studies of patients with acute respiratory distress syndrome (ARDS) and other acute viral illnesses. Notably, however, few studies have ever investigated the biologic mechanisms underlying these functional impairments. Understanding these features of COVID-19 will improve the ability to design acute therapies and recovery-focused interventions. To address these knowledge gaps, the investigators propose a two-center, 225 patient longitudinal prospective cohort study of hospitalized COVID-19 patients with acute respiratory failure. Researchers will perform an in-depth evaluation of inflammatory/immunological biomarkers, and physical, pulmonary, and neuropsychological clinical outcomes during hospitalization, and over 3-, 6-, and 12-month follow-up.
Description: Exercise capacity
Measure: Six minute walk distance (6MWD) Time: 3 months after hospital admissionDescription: Exercise capacity
Measure: Six minute walk distance (6MWD) Time: 6 months, 12 months after hospital admissionDescription: Symptoms of anxiety and depression. Both anxiety and depression subscales are scored from 0-21, with higher scores indicating more symptoms.
Measure: Hospital Anxiety and Depression Scale (HADS) Time: 3 months, 6 months, 12 months after hospital admissionDescription: Health-related quality of life. The EQ-5D-5L is scored from 0-100, with a higher score indicating better health status.
Measure: EuroQol Group standardized measure of health status (EQ-5D-5L) Time: 3 months, 6 months, 12 months after hospital admissionDescription: Mental and Cognitive Functioning. The MoCA-BLIND is scored from 1-22, with higher scores indicating better cognitive function.
Measure: MoCA-BLIND Time: 3 months, 6 months, 12 months after hospital admissionDescription: Health Care Utilization
Measure: Health Care Utilization Survey (HUS) Time: 3 months, 6 months, 12 months after hospital admissionDescription: Mortality
Measure: Death Time: 3 months, 6 months, 12 months after hospital admissionDescription: The maximum volume of gas expired when the patient exhales as forcefully and rapidly as possible after a maximal inspiration. Obtained by spirometry.
Measure: Forced vital capacity (FVC) Time: 3 months, 6 months, 12 months after hospital admissionDescription: Measure of the volume expired over the first second of an FVC maneuver. Obtained by spirometry
Measure: Forced expiratory volume in 1 second (FEV1) Time: 3 months, 6 months, 12 months after hospital admissionDescription: Gait speed
Measure: 4-meter timed walk Time: 3 months, 6 months, 12 months after hospital admissionDescription: Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
Measure: Peripheral blood mononuclear cell type: CD4+ T cells (#cells/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
Measure: Peripheral blood mononuclear cell type: CD8+ T cells (#cells/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
Measure: Peripheral blood mononuclear cell type: B cells (#cells/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
Measure: Peripheral blood mononuclear cell type: NK cells (#cells/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Measured by cell staining and flow cytometry. PBMC differentiation/ activation/exhaustion status will be determined by multicolor flow cytometry staining with human monoclonal antibodies.
Measure: Peripheral blood mononuclear cell type: monocytes (#cells/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: C-Reactive Protein (CRP) (mg/l) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Interleukin 6 (IL-6) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Interleukin 8 (IL-8) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Interferon gamma (IFNg) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Interferon alpha (IFNa) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Tumor necrosis factor alpha (TNFa) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionDescription: Biomarkers measured from plasma will be assayed using Luminex-based multiplex immunoassay.
Measure: Circulating markers of inflammation: Interleukin 1 beta (IL-1b) (pg/ml) Time: study days 1, 3, and 7; then 3 months, 6 months, 12 months after hospital admissionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports